Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Teva pharmaceutical industries ltd symbols : Teva save search
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.23%
H: 0.23%
C: -1.28%
austedo for meeting
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Published: 2024-04-09 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.7%
H: 0.07%
C: -0.92%
first conference teva financial results
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Published: 2024-04-04 (Crawled : 00:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
candidate biosimilar global for teva agreement
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
Published: 2024-02-20 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 1.31%
H: 0.67%
C: -0.91%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
antibody meeting teva
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
Published: 2024-01-02 (Crawled : 00:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.29%
H: 3.53%
C: 1.91%
conference year teva financial results
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
Published: 2023-12-06 (Crawled : 10:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.1%
H: 1.09%
C: -2.38%
ajovy obesity migraine
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
Published: 2023-11-17 (Crawled : 16:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.91%
H: 2.6%
C: 2.38%
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 0.94%
H: 1.8%
C: 0.1%
forteo approval teva
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Published: 2023-11-13 (Crawled : 13:30) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.92%
H: 4.53%
C: 2.56%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: -0.44%
H: 0.59%
C: 0.04%
pharma royalty teva program
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Published: 2023-11-08 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 2.54%
H: 3.23%
C: -1.29%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
revenue teva financial results
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
Published: 2023-10-17 (Crawled : 08:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.69%
H: 1.27%
C: -0.23%
ajovy depression teva migraine study
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-10-04 (Crawled : 08:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 1.46%
H: 0.21%
C: -5.65%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
disease treatment collaboration teva sanofi
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Published: 2023-09-06 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.31%
H: 0.1%
C: -0.52%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -1.87%
H: 0.0%
C: 0.0%
conference global teva
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.31%
H: 0.1%
C: -0.52%
austedo congress teva
Teva Reports Second Quarter 2023 Financial Results
Published: 2023-08-02 (Crawled : 15:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 5.55%
H: 8.46%
C: 5.71%
teva financial results
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
Published: 2023-07-27 (Crawled : 14:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.23%
H: 1.18%
C: -0.94%
business grant teva
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
Published: 2023-07-05 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.4%
H: 2.93%
C: -0.27%
conference teva financial results
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
Published: 2023-06-02 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.69%
H: 0.14%
C: -0.28%
austedo teva
Teva Launches New “Pivot to Growth” Strategy
Published: 2023-05-18 (Crawled : 13:20) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 3.94%
H: 3.67%
C: -2.25%
teva
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.